Press release
Pegfilgrastim Biosimilars Market Emerging Trends, Revenue, Industry Size, Share, Business Growth And Competitive Outlook To 2031: Mylan, Biocon, Pfizer, Sandoz
'Pegfilgrastim Biosimilars Global Market Report 2022 - Market Size, Trends, And Global Forecast 2022-2026' by The Business Research Company is the most comprehensive report available on this market, with analysis of the market's historic and forecast growth, drivers and restraints causing it, and highlights of the opportunities that companies in the industry can take on. The pegfilgrastim biosimilars market research report helps gain a truly global perspective of the pegfilgrastim biosimilars industry as it covers 60 geographies worldwide. Regional and country breakdowns give an analysis of the market in each geography, with information on the size of the market by region and by country.The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest pegfilgrastim biosimilars market share.
Request For A Sample Of The Pegfilgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp
The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services offered by the companies that develop and manufacture them. Pegfilgrastim is a version of filgrastim (Neupogen), used to increase the production of infection-fighting white blood cells for the treatment of cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars find their applications in reducing infection for patients undergoing anticancer therapy.
Key competitors in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi.
The global pegfilgrastim biosimilars market size is expected to grow from $1.17 billion in 2021 to $1.28 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pegfilgrastim biosimilars market is expected to reach $1.92 billion in 2026 at a CAGR of 10.6%.
Need More For Your Business Growth? Directly Purchase The Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015
TBRC's report segments the global pegfilgrastim biosimilars market:
1) By Application: Chemotherapy Treatment, Transplantation, Others
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
Read Further On The Pegfilgrastim Biosimilars Market Here:
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
The Table Of Contents Includes:
1. Executive Summary
2. Pegfilgrastim Biosimilars Market Characteristics
3. Pegfilgrastim Biosimilars Market Trends And Strategies
4. Impact Of COVID-19 On Pegfilgrastim Biosimilars
5. Pegfilgrastim Biosimilars Market Size And Growth
.....
28. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market
29. Pegfilgrastim Biosimilars Market Future Outlook And Potential Analysis
30. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
And check out our Blog: http://blog.tbrc.info/
Interested To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegfilgrastim Biosimilars Market Emerging Trends, Revenue, Industry Size, Share, Business Growth And Competitive Outlook To 2031: Mylan, Biocon, Pfizer, Sandoz here
News-ID: 2566344 • Views: …
More Releases from The Business research company

Surgical Meshes Market Landscape to 2034: Key Forces Shaping the Next Decade of …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Surgical Meshes Market Size By 2025?
In the past few years, the market size of surgical meshes has seen significant growth. It is projected to expand from $2.03 billion in 2024 to $2.18 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 7.3%.…

Rehabilitation Equipment Market Poised to Hit $23.97 Billion by 2029 with Accele …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Rehabilitation Equipment Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a significant growth in the size of the rehabilitation equipment market. Projected to increase from $17.36 billion in 2024, it is expected to reach $18.49 billion in 2025, with a compound annual…

Future of the Pediatric Neurology Device Market: Strategic Analysis and Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pediatric Neurology Device Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pediatric neurology devices has seen significant expansion in recent years, climbing from $2.5 billion in 2024 to an anticipated $2.65 billion in 2025, reflecting a compound annual growth rate (CAGR)…

Key Trends Influencing the Growth of the Orthokeratology Lens Market in 2025: In …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Orthokeratology Lens Market Through 2025?
The market for orthokeratology lenses has seen a significant increase in size over recent years. It's projected to expand from $2.56 billion in 2024 to $2.75 billion in 2025, with a compound annual growth rate (CAGR) of…
More Releases for Pegfilgrastim
Pegfilgrastim Biosimilar Market: Emerging Trends and Growth Forecast to 2033
The global Pegfilgrastim Biosimilar Market, valued at approximately USD 1.56 billion in 2024, is projected to reach around USD 6.36 billion by 2033, growing at a CAGR of 17.1% from 2025 to 2033.
Pegfilgrastim Biosimilar Market Overview
The Pegfilgrastim Biosimilars Market is experiencing rapid growth due to the increasing prevalence of cancer and the rising demand for cost-effective treatment alternatives to branded biologics. Pegfilgrastim, used to prevent neutropenia in cancer patients undergoing…
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation…
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars.
The report highlights that the evolving global scenario of cancer management and treatment is fostering…
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia.
Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Neutropenia patients are highly…
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts.
Pegfilgrastim is a PEGylated…
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by…